Bristol Myers Squibb, CAMZYOS, Mavacamten, FDA Approval, Obstructive Hypertrophic Cardiomyopathy, oHCM, Pediatric Cardiology

PRINCETON, New Jersey, September 30, 2026 Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has...